Industry professionals anticipate that China's drug sales will exceed US$50 billion this year

Business Club March 25th: President Xie Lie Lie, the president of Bayer HealthCare China, disclosed the latest figures: In 2011, the total pharmaceutical sales in mainland China is expected to exceed US$50 billion, which will become the third largest pharmaceutical market in the world.

Li Xilie’s "2010 Annual Review of the Chinese Market" provided at a media symposium held here said that the enormous potential contained in the Chinese pharmaceutical market provides a good platform for the development of the global pharmaceutical market. The Chinese government's continuous investment in health care, aging population, the growing public demand for chronic diseases, and the growth of the macro economy will all maintain the sustained high-speed development of the Chinese pharmaceutical market.

According to statistics, as of 2009, the Chinese pharmaceutical market had a profit of RMB430 billion, of which about 60% came from the pharmaceutical market, and retail channels accounted for 28%. Anti-infectives, digestive tract and metabolism, and cardiovascular drugs accounted for The top three sales; anti-tumor class is expected to replace cardiovascular drugs in 2014 to become the third largest therapeutic drug.

Li Xilie believes that China’s medical reforms, which cost US$125 billion, have a positive impact on multinational pharmaceutical companies. As the first Chinese multinational pharmaceutical company to enter, Bayer will seize China's growth opportunities and continue to maintain long-term and sustainable growth. He disclosed that he will start a new strategy of regionalization structure, increase staff development business scale, improve the efficiency of Chinese market operations, and better meet the needs of patients in different regions.

It is understood that Bayer HealthCare is currently one of the three largest foreign pharmaceutical companies in China. Last year, its prescription drug business grew by 22%, and four new drugs including hormone replacement therapy and recombinant human insulin were introduced. In order to implement the innovation strategy in China, the Group established the fourth global research and development center in Beijing in 2009, and cooperated with the National Engineering Research Center for Pharmaceutical Preparations, the PLA General Hospital, and Tsinghua University to develop new drugs.

Bayer HealthCare, headquartered in Germany, is a subsidiary of Bayer AG. Last year, global sales revenue reached 16.9 billion euros; currently has production bases in Beijing, Guangzhou, Chengdu and Jiangsu, this year will set up a regional office in Chengdu, Sichuan to manage the entire western market .